Cart
Products
<< Back to MOTIFvations Blog Home Page
Battling Cancer with an NRAS Mutant-specific Monobody
June 9, 2025
Table of Contents:
Introduction: The Problem of Targeting Mutant NRAS in Cancer
The RAS GTPase isoforms HRAS, KRAS, and NRAS regulate crucial intracellular signaling cascades that control cell proliferation and survival (Karnoub and Weinberg); furthermore, they represent some of the most frequently mutated oncogenes in human cancers. We currently lack targeted therapies for NRAS-mutated cancers, which include melanoma, multiple myeloma, and colorectal cancer (Prior et al. (a) and Prior et al. (b)) even though recent years have seen advancements in the development of anti-RAS therapeutics. Overall, the description of clinical trials of KRAS inhibitors in non-small cell lung cancer (Jänne et al. and Skoulidis et al.) and pre-clinical reports of non-covalent, selective mutant-specific and pan-KRAS inhibitors (Wang et al. and Kim et al.) have provided some encouragement.
As an alternative to small-molecule RAS inhibitors, researchers from the laboratories of Shohei Koide (NYU) and John P. O’Bryan (Medical University of South Carolina) have developed “monobodies” that interact with and inhibit specific RAS isoforms or mutants (Spencer-Smith et al. (a), Khan et al. (a), and Spencer-Smith et al. (b)). Monobodies - synthetic binding proteins constructed employing a fibronectin type III domain as a molecular scaffold (Hantschel et al.) – represent a simple and robust alternative to antibodies for creating target-binding proteins.
While the selective targeting of NRAS by monobodies faced challenges associated with molecular recognition, a recent study from the Koide and O´Bryan laboratories reported in Oncogene describes a newly developed inhibitory NRAS monobody as a novel “weapon” in the battle against cancer. This study describes how “Mb24” can bind to GDP/GTP-bound states of NRAS, inhibit NRAS-mediated signaling, and form a component of a genetically encoded NRAS-specific degrader (Whaby et al. (a)). Does the development of this new, highly specific monobody now offer a means of efficiently battling NRAS mutant cancers?
Mb24 – Development, Analysis of Mechanism of Action, and Potential Therapeutic Applications
The development of Mb24 employed established methods that combine phage and yeast display technologies (Khan et al. (b), Teng et al., and Koide et al.), positive (GDP/GTP-bound NRAS) and negative (GDP/GTP-bound HRAS and KRAS) selection methodologies, and the confirmation of specificity in immortalized human cells, where Mb24 selectively co-precipitated with two different NRAS mutants. Whaby et al. next demonstrated that Mb24 specifically inhibited ERK/MAPK signaling mediated by epidermal growth factor-stimulated wild-type NRAS and oncogenic NRAS mutants thanks to the implementation of two cell models - the “RASless” HEK 293 model cellular system (Cuevas-Navarro et al.) and the Flp-In FRT system (generates cells that stably express single RAS isoforms). Next, the authors confirmed that Mb24 inhibited the biological activity of oncogenic NRAS mutants, finding that the induced expression of Mb24 in NRAS mutant cancer cells (but not wild-type NRAS cancer cells) effectively decreased ERK/MAPK phosphorylation (indicating reduced signaling activity) and significantly reduced anchorage-independent cell growth and cell migration (suggesting the loss of cancer cell-like characteristics).
Analysis of the mechanisms controlling Mb24-driven NRAS inhibition evaluated the effect of Mb24 on crucial protein:protein interactions occurring in the RAS/MAPK signaling pathway in live cells thanks to the application of NanoBiT technology (Whaby et al. (b)). This approach discounted NRAS interactions with CRAF but suggested that Mb24 can disrupt oncogenic CRAF:BRAF heterodimerization and inhibit NRAS by sterically interfering with nanoclustering at the plasma membrane to inhibit NRAS-stimulated RAF dimerization and activation.
Finally, the authors aimed to increase the utility of Mb24 by deploying this specific monobody as a “warhead” that prompted the targeted proteasomal degradation of mutant NRAS as a potential anti-cancer approach (Teng et al., Akkapeddi et al., and Lim et al.). To do so, the authors genetically fused Mb24 to a truncated version of the VHL E3 ligase (Teng et al.) and revealed that Mb24 could target VHL E3 ligase activity to NRAS, which supported the proteasome-dependent degradation. Overall, the authors provide evidence that the VHL-Mb24 fusion protein represents a new weapon that can target NRAS mutant cancers.
Mb24 – The Future of the Battle Against NRAS Mutant Human Cancers?
Overall, this first report of Mn24 as a highly specific and effective “weapon” highlights a new avenue for the development of NRAS-selective therapeutics that will significantly aid in the battle against certain types of cancer.
Active Motif can help in the battle against cancer with a range of RAS GTPase-related products, which include the Ras GTPase Chemi ELISA Kit for the rapid and sensitive analysis of activated Ras GTPase and the KRAS In-well Lysis ELISA Kit for the rapid, sensitive, and highly specific quantification of active KRAS.
For more details on how an NRAS mutant-specific monobody may represent a new tool in the battle against cancer, see Oncogene, October 2024.
About the author
Stuart P. Atkinson, Ph.D.
Stuart was born and grew up in the idyllic town of Lanark (Scotland). He later studied biochemistry at the University of Strathclyde in Glasgow (Scotland) before gaining his Ph.D. in medical oncology; his thesis described the epigenetic regulation of the telomerase gene promoters in cancer cells. Following Post-doctoral stays in Newcastle (England) and Valencia (Spain) where his varied research aims included the exploration of epigenetics in embryonic and induced pluripotent stem cells, Stuart moved into project management and scientific writing/editing where his current interests include polymer chemistry, cancer research, regenerative medicine, and epigenetics. While not glued to his laptop, Stuart enjoys exploring the Spanish mountains and coastlines (and everywhere in between) and the food and drink that it provides!
Contact Stuart on X with any questions
Related Articles
The Search for a Therapeutic Chink in Inhibitor-resistant an NRAS Mutant Tumor’s Armour
May 27, 2025
While searching for a therapeutic vulnerability in MAPK inhibitor-resistant NRAS mutant tumors, researchers led by Jessie Villanueva at the Wistar Institute identified S6K2 as a potential chink in melanoma´s armor. Catch up on their findings in our latest overview of NRAS mutation biology and approaches!
Read More
Keeping Up to Date with KRAS-driven Cancer
July 14, 2023
Oncogenic mutations in the KRAS proto-oncogene lead to the generation of proteins that drive the development of lung, colorectal, and pancreatic cancers. Patients with these types of KRAS-driven tumors have historically faced significant treatment challenges. The development of new strategies to target KRAS driven cancer has the potential to save thousands of lives each year. In this blog we discuss some of the exciting studies that have propelled the KRAS-centered cancer research field forward in recent months.
Read More
Strategies for KRAS Research and Drug Discovery
March 8, 2023
RAS is one of the most common oncogenes, responsible for 20-30% of all human cancers, with KRAS being responsible for most of these. Current research has mostly focused on targeting KRAS mutants, but it’s only been in the last decade that we’ve seen development of methods to directly inhibit mutant KRAS. With new insight into mechanisms behind KRAS activation there is an ever-expanding pipeline of potential drugs which may change the way these dangerous cancers are treated. Here we provide a look at the history of RAS family proteins in the context of mutations and potentially targets to mitigate their action.
Read More
<< Back to MOTIFvations Blog Home Page
